Biomarin Pharmaceutical (BMRN) Net Income towards Common Stockholders Growth (5y) (2014 - 2026)
Powered by 
Analysis
Biomarin Pharmaceutical (BMRN) Net Income towards Common Stockholders Growth (5y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Biomarin Pharmaceutical | 12.88 Bn | 12.01 Bn | 786.91 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 28.17% |
| Mar 31, 2026 | 43.45% |
| Dec 31, 2025 | -36.48% |
| Sep 30, 2025 | -15.32% |
| Jun 30, 2025 | 59.25% |
| Mar 31, 2025 | 17.94% |
| Dec 31, 2024 | 52.75% |
| Sep 30, 2024 | 14.02% |
| Jun 30, 2024 | 37.21% |
| Mar 31, 2024 | 28.98% |
| Dec 31, 2023 | 49.95% |
| Sep 30, 2023 | 39.06% |
| Jun 30, 2023 | 39.79% |
| Mar 31, 2023 | 25.81% |
| Dec 31, 2022 | -15.09% |
| Sep 30, 2022 | 11.89% |
| Jun 30, 2022 | 22.43% |
| Mar 31, 2022 | 56.59% |
| Dec 31, 2021 | -142.32% |
| Sep 30, 2021 | 0.50% |